Larry Tsai
Nessuna posizione attualmente
Storia della carriera di Larry Tsai
Precedenti posizioni note di Larry Tsai
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 02/01/2018 | 24/06/2019 |
| Corporate Officer/Principal | 01/01/2014 | 02/01/2018 | |
Aeris Therapeutics LLC
 Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2002 | 01/01/2011 |
Formazione di Larry Tsai
| Stanford University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Larry Tsai
- Esperienza
